Supernus Pharmaceuticals develops and commercializes specialty medicines focused largely on central nervous system disorders. Its marketed products address conditions such as ADHD, epilepsy and Parkinson’s disease, often with extended-release or differentiated formulations. The company targets neurologists, psychiatrists and other specialists in the U.S., combining branded prescription brands with a pipeline of CNS assets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 165.4 | — | 22.5 | — |
| Q3 2025 | 192.1 | — | -45.1 | — |
| Q4 2025 | 211.6 | — | -4.1 | — |
| Q1 2026 | 207.7 | — | -2.3 | — |
| Q2 2026 | 219.1 | 32.4% | -58.4 | -359.4% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Aurinia Pharmaceuticals Inc. (AUPH), Stagwell Inc. (STGW), ChronoScale Holdings Corporation (CHRN), Navitas Semiconductor Corporation (NVTS), Northwest Bancshares, Inc. (NWBI), Patrick Industries, Inc. (PATK)